Recursion Pharmaceuticals CEO Gibson Christopher Sells 100,000 Shares for $4.84 Each.

Recursion Pharmaceuticals, Inc. (RXRX) announced that Director and Chief Executive Officer Gibson Christopher sold 100,000 shares at a price of $4.84 per share on August 26, 2025.

Recursion Pharmaceuticals, Inc. (RXRX) announced that Director and Chief Executive Officer Christopher Gibson sold 100,000 shares of the company's Class A common stock at a price of $4.84 per share on August 26, 2025. The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on May 12, 2025, indicating pre-arranged trading and procedural compliance [1].

Gibson's sale follows a period of significant volatility in the stock, with the company's shares shedding more than 17% of their value week-to-date as of Thursday night. This decline was partly attributed to an analyst price target cut by Sean Laaman from Morgan Stanley and the sale of large piles of stock by several top managers, including Gibson and Chief R&D and Commercial Officer Najit Khan [2].

The filing disclosed that Gibson's sale was part of a broader insider liquidity event, with the shares sold to satisfy tax withholding and remittance obligations related to the vesting of restricted stock units. The sale did not represent a significant change in Gibson's overall equity exposure, as he retains substantial direct holdings and substantial outstanding stock options across multiple strike prices.

For investors, this is a transparent, preplanned liquidity event rather than an unscheduled insider disposition. The use of a documented 10b5-1 plan and the attorney-in-fact signature in the filing provide procedural compliance and align with standard governance transparency for executive transactions.

References:
[1] https://www.stocktitan.net/sec-filings/RXRX/form-4-recursion-pharmaceuticals-inc-insider-trading-activity-c260f28f84e4.html
[2] https://finance.yahoo.com/news/why-recursion-pharmaceuticals-stock-caught-215300552.html